We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $60.63 in the latest trading session, marking a +1.9% move from the prior day. This change outpaced the S&P 500's 0.27% loss on the day. At the same time, the Dow added 0.4%, and the tech-heavy Nasdaq lost 0.18%.
Heading into today, shares of the vaccine maker had lost 23.49% over the past month, lagging the Medical sector's gain of 9.59% and the S&P 500's gain of 7.36% in that time.
Novavax will be looking to display strength as it nears its next earnings release. In that report, analysts expect Novavax to post earnings of $3.30 per share. This would mark year-over-year growth of 208.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.11 million, up 98.58% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $22.84 per share and revenue of $4.57 billion. These results would represent year-over-year changes of +197.44% and +298.65%, respectively.
Investors should also note any recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Novavax is currently a Zacks Rank #4 (Sell).
In terms of valuation, Novavax is currently trading at a Forward P/E ratio of 2.61. Its industry sports an average Forward P/E of 22.94, so we one might conclude that Novavax is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Gains As Market Dips: What You Should Know
Novavax (NVAX - Free Report) closed at $60.63 in the latest trading session, marking a +1.9% move from the prior day. This change outpaced the S&P 500's 0.27% loss on the day. At the same time, the Dow added 0.4%, and the tech-heavy Nasdaq lost 0.18%.
Heading into today, shares of the vaccine maker had lost 23.49% over the past month, lagging the Medical sector's gain of 9.59% and the S&P 500's gain of 7.36% in that time.
Novavax will be looking to display strength as it nears its next earnings release. In that report, analysts expect Novavax to post earnings of $3.30 per share. This would mark year-over-year growth of 208.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.11 million, up 98.58% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $22.84 per share and revenue of $4.57 billion. These results would represent year-over-year changes of +197.44% and +298.65%, respectively.
Investors should also note any recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Novavax is currently a Zacks Rank #4 (Sell).
In terms of valuation, Novavax is currently trading at a Forward P/E ratio of 2.61. Its industry sports an average Forward P/E of 22.94, so we one might conclude that Novavax is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.